Fundraising FoxImmune-Onc Therapeutics
Palo Alto, US · Founded 2015 · Delaware corporation · 9 known investors
Find your way into Immune-Onc Therapeutics
Sign up to see every warm intro you have to Immune-Onc Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Immune-Onc Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Immune Onc is a biotechnology company developing medicines to treat patients with hard-to-treat cancers and autoimmune diseases, with expertise in translational medicine and clinical development.
Founders & leadership
Immune-Onc Therapeutics was founded in 2015 by Xiaoling Charlene Liao.
Board
Investors · 9
How we know: CLI Ventures's portfolio page · Not right? Tell us
How we know: Northern Light Venture Capital's portfolio page · the VCSheet dataset · Not right? Tell us
How we know: ShangBay Capital LLC's portfolio page · Not right? Tell us
How we know: StartX's portfolio page · Not right? Tell us
How we know: Vivo Capital's portfolio page · funding news · Not right? Tell us
How we know: immune-onc.com · Not right? Tell us
Also in the syndicate · 3
Funding
SEC filings, press & company announcements$7M disclosed across 1 of 3 rounds · 2016–2023
- Undisclosed amountSeries B extensionJan 2023
Triwise Capital (lead), Proxima Ventures, The Leukemia & Lymphoma Society’s Therapy Acceleration Program®, Wuxi Biologics HealthCare Venture
Source ↗ - Undisclosed amountSeries BSep 2018Source ↗
▶$7MraisedSep 2016 · 14 investors · BiotechnologyRule 506(b)
- Xiaoling Charlene LiaoExecutive Officer, Director
- Guo-Liang YuDirector
- Liqun LuoDirector
- Offering amount
- $7M
- Amount sold
- $7M
- Minimum investment
- $1
- First sale
- Jul 2016
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 7
Companies working in the same space as Immune-Onc Therapeutics.
Non-dilutive funding · 1 SBIR/STTR award
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2020 | $2.1M |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- What does Immune-Onc Therapeutics do?
- Immune Onc is a biotechnology company developing medicines to treat patients with hard-to-treat cancers and autoimmune diseases, with expertise in translational medicine and clinical development.
- Who founded Immune-Onc Therapeutics?
- Immune-Onc Therapeutics was founded by Xiaoling Charlene Liao in 2015.
- Who are Immune-Onc Therapeutics's investors?
- Immune-Onc Therapeutics's investors include CLI Ventures, Northern Light Venture Capital, ShangBay Capital LLC, StartX, Vivo Capital, TriWise Capital.
- How much funding has Immune-Onc Therapeutics raised?
- Immune-Onc Therapeutics has disclosed $7M raised across 1 of its 3 known rounds.
- Where is Immune-Onc Therapeutics headquartered?
- Immune-Onc Therapeutics is headquartered in Palo Alto, US.